Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy

Allergy, Asthma & Clinical Immunology 2017, 13:45 | Published on: 3 November 2017

I. J. Pouliquen, P. Howarth, D. Austin, G. Gunn, E. Meyer, R. G. Price and E. Bradford

To the Editor,

We read with interest the case report and accompanying discussion published by Mukherjee et al. (AACI 2017;13:2) of a 62-year old woman diagnosed with severe eosinophilic asthma. This clinical case presents a patient with progressive deterioration in FEV1 function since 2011 with no improvement observed while receiving OCS, hydroxyurea or imatinib therapy. On this background of deterioration, the patient entered the double-blind placebo controlled clinical trial MEA115575 and received mepolizumab 100 mg s.c. every 4 weeks. Further deterioration in FEV1 coincided with the (protocol defined) reduction in prednisolone during the study, and neither intravenous solumedrol nor pre-study prednisolone doses improved FEV1 to pre-study values. During the open-label mepolizumab extension study MEA115661 the patient’s clinical status was unchanged. In January 2015, 9 months after their last dose of mepolizumab, the patient further deteriorated whilst receiving azathioprine immunosuppressive therapy. This clinical case presentation clearly underlines the aggressive nature...

 

Full Text | PDF

 

 

 

 

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: Jason K Lee on Twitter: "Potential treatment for pollen food syndrom… https://t.co/SHnw9UVPnw, see more https://t.co/CpGiFuOOYd
14mreplyretweetfavorite
Interasma Top story: @worldallergy: '#EAACI2018 Understanding phenotypes and endotypes in… https://t.co/WcFkKLobbc, see more https://t.co/CpGiFuOOYd
2hreplyretweetfavorite
Interasma Top story: EAACI on Twitter: "Announcing #EAACI2018 #SisterSocietySymposium SSS… https://t.co/Wic8jRgFE8, see more https://t.co/CpGiFuOOYd
6hreplyretweetfavorite
Interasma Top story: Graham Roberts on Twitter: "Severe asthma plenary #EAACI2018 - no me… https://t.co/ssW67QWKyG, see more https://t.co/CpGiFuOOYd
18hreplyretweetfavorite
Interasma RT @worldallergy: #EAACI2018 Understanding phenotypes and endotypes in severe #asthma https://t.co/MMyACUQd5c
20hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma